The lower Keap1 protein levels in ARB after 6 wks of treatment suggests that the ability of ARB to ameliorate the insulin resistance-associated oxidative damage observed in OLETF rats and other models of diabetes and metabolic syndrome may be achieved by decreasing cytosolic Keap1. Here, KEAP1 is linked to metabolic syndrome.